TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 372.44%의 증가율을 기록했습니다.
이익 전환
회사의 실적이 흑자로 전환되어, 최근 연간 순이익은 미화 35.46M달러에 달합니다.%!(EXTRA int=2)
공정한 가치
회사의 최신 PE은 53.75로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 42.27M주이며, 전 분기 대비 5.17% 감소했습니다.
더 뱅가드가 보유
스타 투자자 더 뱅가드이(가) 이 주식 3.59M주를 보유하고 있습니다.